VB4-845

Vicinium™

Vicinium™ is Viventia’s product candidate for the treatment of non-invasive transitional cell carcinoma (TCC) of the bladder, the second most common malignancy of the genitourinary system. Vicinium™ is being investigated for use in patients refractory or intolerant to Bacillus Calmette-Guérin (BCG) therapy. BCG is associated with safety and tolerability concerns and is contraindicated in many patients. Combined with a high recurrence rate, many patients are left with limited therapeutic options and the possibility of cystectomy.

Vicinium™ has been evaluated in a Phase I/II clinical trial, and a Phase II efficacy trial to assess safety, tolerability and clinical efficacy. The Phase II trial with 46 BCG refractory Carcinoma in Situ (CIS) patients has demonstrated that Vicinium™:

• Is safe and very well tolerated with no significant toxicity
• Is effective in BCG refractory CIS patients with an overall Complete Response (CR) rate of 40% at 3 months and 29% at 6 months
• Has durable response up to at least 12 months in 17% of patients
• Warrants further development not only for refractory patients with CIS but also for the early treatment of all stages of non-invasive TCC       

Given Vicinium™’s unique mechanism of action, Viventia anticipates that Vicinium™ can also be used in conjunction with other bladder cancer treatments such as TURBT, BCG, BCG analogs, and chemotherapeutics.

For more information, click here to download our Vicinium™ Licensing Brochure